Purpose: The widespread use of 68 Ga for positron emission tomography (PET) relies on the development of radiopharmaceutical precursors that can be radiolabelled and dispensed in a simple, quick, and convenient manner. The DATA (6-amino-1,4-diazapine-triacetate) scaffold represents a novel hybrid chelator architecture possessing both cyclic and acyclic character that may allow for facile access to 68 Ga-labelled tracers in the clinic. We report the first bifunctional DATA chelator conjugated to [Tyr 3 ]octreotide (TOC), a somatostatin subtype 2 receptor (SST 2 )-targeting vector for imaging and functional characterisation of SSTR 2 expressing tumours.
Background
There has been a surge in the development of 68 Ga-radiopharmaceuticals over the last decade initiated by the clinical and commercial success of [ 68 Ga]Ga-DOTA-TOC (TOC: DPhe-c[Cys-Tyr-DTrp-Lys-Thr-Cys]-Thr-ol) and [ 68 Ga]Ga-DOTA-TATE (TATE: DPhe-c[Cys-Tyr-DTrp -Lys-Thr-Cys]-Thr-OH), as well as by significant improvements in the provision of 68 Ga generators now fulfilling pharmaceutical standards [1] [2] [3] [4] [5] [6] .
As a result, [ 68 Ga]Ga-DOTA-TOC and [ 68 Ga]Ga-DO-TA-TATE are currently being used in clinical settings for the diagnosis of neuroendocrine tumours (NETs). Furthermore, [ 68 Ga]Ga-DOTA-TATE acquired FDA approval as a diagnostic PET radiopharmaceutical for the visualisation of NET lesions (FDA News Release, June 1, 2016) , following the 'orphan drug' designation to [ 68 Ga]Ga-DOTA-TOC by FDA [7] , and [ 68 Ga]Ga-DO-TA-TOC was approved by European Medicines Agency. Due to the availability of 68 Ga via commercial 68 Ge/ 68 Ga generators and favourable emission characteristics for PET imaging (β + = 89%, E β,max = 1.9 MeV), the facile and efficient access to 68 Ga-radiopharmaceuticals is expected to drive the use of 68 Ga in PET centres [1, [8] [9] [10] [11] . A key step in this direction is the development of simple, effective, robust, and reliable labelling protocols, which depend primarily on the chelating moiety of the bifunctional chelator (BFC) attached to the vector of interest. Established BFCs based on a DOTA or DO3A scaffold for 68 Ga require relatively harsh conditions (a balance of high temperatures, low pH, and high concentrations of the precursor) for efficient radiolabelling [2, 12] . This restriction inherently limits the portfolio of 68 Ga-radiopharmaceuticals, because several promising peptide-, protein-, and antibody-based vectors for application in nuclear oncology are temperature and/or pH sensitive [13] . Thus, the radiolabelling of such molecules imposes stringent requirements on the BFC, i.e. > 95% labelling efficiency at ambient temperatures, less acidic conditions, and at high molar activities. Moreover, in the case of short-lived radionuclides, like 68 Ga (t 1/2 = 67.7 min), shorter labelling times and simple preparations are highly desirable, leading to a ready-for-injection radiolabelled product that does not require further purification prior to use. The development of such labelling protocols should be seen as mandatory to fully exploit the aforementioned advantages of 68 Ga, but presents significant challenges in the design of suitable BFCs [14] .
In general, chelators (Additional file 1: Figure S1 ) can be distinguished as cyclic (DOTA, NOTA, TRAP), associated with high thermodynamic stability, or acyclic (DFO, DTPA, HBED, THP), linked to a high kinetic stability that allows for higher labelling efficiency [12, [15] [16] [17] [18] [19] . For example, Blower et al. demonstrated that THP derivatives are superior in terms of labelling kinetics [20] compared to BFCs with cyclic chelating functionalities and the novel THP-conjugated radiopharmaceuticals are under evaluation to prove their full viability in vivo for different targeting vectors.
Special chelators like TRAP offer good properties in general, but are predominantly seen in the context of multivalent applications. The DATA scaffold represents a unique approach to chelator design in that the chelating moiety is a hybrid, possessing both cyclic and acyclic character. It is believed that flexibility of the acyclic portion (6′ nitrogen and associated acetate function) facilitates rapid complexation, whilst the preorganised cyclic portion minimises the energy barrier to complexation and inhibits decomplexation processes [21, 22] . The favourable radiolabelling kinetics of the DATA chelators, ambient temperature, and pH 4-6.5, along with the excellent stability of the forming 68 Ga-chelates, justified the development of a bifunctional derivative [23] . We recently reported on the synthesis and 68 Ga-radiolabelling of the first DATA peptide conjugate, DATA-TOC (Fig. 1) [23] .
Following the promising results of the initial work with uncoupled DATA-BFCs, the aim was to evaluate the suitability of a DATA-BFC with an established vector for comparison with the current clinical standard. Therefore, [ 68 Ga]Ga-DATA-TOC was selected as the first target for comparison with [
68 Ga]Ga-DOTA-TOC as the clinically established reference in a series of biological in vitro and in vivo models expressing the somatostatin subtype 2 receptor (hSST 2 ), specifically (i) competition binding assays in human SST 2/3/5 -positive cell membranes, (ii) biodistribution and small animal PET imaging in a preclinical mCherry-expressing mouse phaeochromocytoma (MPC-mCherry) model with high SST 2 density [24, 25] , and (iii) clinical studies in a patient previously diagnosed with NETs. This direct comparison will reveal the influence of a DOTA-to-DATA chelator-switch on the biological behaviour of 68 Ga-labelled DOTA-TOC.
Materials and methods
DATA-TOC was synthesised as previously described [23] LTT-SS28 (H-Ser-Ala-Asn-Ser-Asn-Pro-Ala-Leu-AlaPro-Arg-Glu-Arg-Lys-Ala-Gly-c[Cys-Lys-Asn-Phe-PheDTrp-Lys-Thr-Tyr-Thr-Ser-Cys]-OH) was purchased from Bachem.
Gallium-68 was eluted from one of two available 68 Ge/ 68 Ga generators (iThemba Labs) using 1.0 M HCl. The final HCl concentration of the eluates from both generators was approximately 1 M. The pH of the fractionated 68 Ga-eluate (300 μL containing 555 MBq (15 mCi) 68 Ga at the start of synthesis) was adjusted to pH 4.0-4.5 using 2.0 M NH 4 OAc. A solution of 68 Ga(OAc) 3 in acetate buffer was added to 20 nmol of each peptide. The reaction mixture was shaken for 10 min at 80°C to afford [ 68 Ga]Ga-DOTA-TOC or at 20°C for 10 min to afford [ 68 Ga]Ga-DATA-TOC. Reaction mixtures were analysed by radio-HPLC.
Radio-HPLC was performed on a Series 1200 (Agilent) HPLC equipped with the Ramona ß/γ-ray radiodetector (Raytest): eluent A 0.1% (v/v) TFA in H 2 O; eluent B 0.1% (v/v) TFA in MeCN; HPLC system Zorbax (Agilent) SB-C18, 300 Å, 4 μm, 250 mm × 9.4 mm; and linear gradient elution using 95% eluent A to 95% eluent B in 10 min, 50°C. Radiolabelled products with radiochemical purity higher than 95% were used for biological experiments after filtering (45 μm pore size, REZIST 13/0.45 PTFE, Schleicher & Schuell) and diluting the labelling reaction mixture. Filtrates were diluted with 0.1 mL electrolyte solution E-153 (Serumwerk Bernburg AG) to a final concentration of~80 MBq/mL [26, 27] .
For the preparation of [ 125 I-Tyr 25 ]LTT-SS28, [ 125 I]NaI was provided by PerkinElmer in dilute sodium hydroxide solution (pH [8] [9] [10] [11] in an activity concentration of 13.52 GBq (365.4 mCi) per mL. Radioiodination was performed according to the chloramine-T method using 0.1 M D,L-methionine to quench the reaction, and the radioligand was isolated by HPLC, as previously described [28] [29] [30] .
Cell culture and in vitro assays
The HEK293 cell line was transfected to stably express each of the hSST 2/3/5 and the resultant HEK293-hSST 2/3/5 cells used for receptor affinity assessments were donated by Prof. S. Schultz (Institute of Pharmacology and Toxicology, University Hospital, Friedrich Schiller University Jena, Germany). Cells were cultured at 37°C and 5% CO 2 in Dulbecco's modified Eagle's medium containing 10% fetal bovine serum, 100 U/mL penicillin, 100 mg/mL streptomycin and 500 mg/mL G418, as previously described [28, 30] . Culture reagents A B were from Gibco BRL, Life Technologies, and Biochrom KG Seromed. The genetically modified MPC-mCherry cells [25] derived from MPC cells (clone 4/30PRR [31] ) characterised by a high density expression of mouse SST 2 [24] were cultured and prepared for in vivo application as previously described [24, 25] .
Competition binding experiments were performed for [ nat Ga]Ga-DATA-TOC and [
nat Ga]Ga-DOTA-TOC in HEK293-hSST 2/3/5 cell membranes, harvested as previously described [29] . Ice-cold washing buffer (10 mM HEPES pH 7.4, 150 mM NaCl) was added, followed by rapid filtration using glass fibre filters (Whatman GF/B, presoaked for 2 h in a 1% polyethyleneimine (PEI) aqueous solution) on a Brandel Cell Harvester (Adi Hassel Ingenieur Büro) washed with ice-cold washing buffer. Filters were collected, and their activity measured in a γ-counter (automated well-type multisample gamma counter; NaI(Tl) 3″ crystal, Canberra Packard Auto-Gamma 5000 series instrument). The half maximal inhibitory concentration (IC 50 ) values were calculated by nonlinear regression according to a one-site model applying the PRISM 2 program (Graph Pad Software) and represent mean IC 50 ± sd from n experiments performed in triplicate for
nat Ga]Ga-DOTA-TOC (n = 2), and LTT-SS28 (n = 3).
Animal studies
A number of 2 × 10 6 MPC-mCherry cells were transplanted subcutaneously into the right shoulder of female NMRI-nude mice (8 to 10 weeks old, RjOrl:NMRIFoxn1 nu /Foxn1 nu , Janvier Labs). Tumour growth was monitored by fluorescence imaging using the in vivo Xtreme optical imaging system (Bruker) [24] under anaesthesia that was induced and maintained by inhalation of 12% and 9% (v/v) desflurane in 30/10% (v/v) oxygen/ air, respectively. Animals were studied when the tumour diameter was 6 to 9 mm.
For biodistribution studies with [ 68 Ga]Ga-DATA-TOC 17 (control n = 9, blocked n = 8) and [ 68 Ga]Ga-DOTA-TOC 12 (control n = 5, blocked n = 7) female mice (body weight 36.3 ± 2.1 g) were injected intravenously into a tail vein with approximately 2.3 MBq (62 μCi)/0.35 nmol peptide (DATA-TOC 11.2 nmol/kg body weight and DOTA-TOC 10.5 nmol/kg body weight) in 0.1 mL electrolyte solution E-153 (Serumwerk Bernburg AG) without (control) or with simultaneous injection of 100 μg/ mouse [Nal 3 ]octreotide acetate (blocked). Animals were sacrificed at 60 min post-injection (p.i.). Blood, tumour, and the major organs were collected, weighed, and counted in a cross-calibrated γ-counter (Isomed 1000, Isomed GmbH) and Wallac WIZARD Automatic Gamma Counter (PerkinElmer). The activity of the tissue samples was decay-corrected and calibrated by comparing the counts in tissue with the counts in aliquots of the injected radiotracer that had been measured in the γ-counter at the same time. The activity in the selected organs was expressed as percent-injected activity per organ (%IA) and the activity concentration in tissues and organs as standardised uptake value (SUV in [MBq activity/g tissue]/[MBq injected activity/g body weight]). Values are quoted as mean ± standard deviation for each group of animals.
PET scans were performed using a dedicated rodent PET/CT scanner (NanoPET/CT, Mediso). Anaesthetised mice (two animals per group) bearing subcutaneous MPC-mCherry-tumours on the right shoulder were positioned on a warmed bed along the scanner axis. The 68 Ga-labelled product, 10 MBq/0.26 nmol/300 μL (8.6 nmol DATA-TOC/kg body weight) and 10 MBq/ 0.26 nmol/300 μL (14.1 nmol DOTA-TOC/kg body weight), was infused over 1 min into a tail vein. PET images were acquired beginning with the injection on a Mediso NanoPET/CT camera and were reconstructed in dynamic mode with 38 frames and 0.5 mm 3 voxel size. Total scan time was 2 h. Region-of-interest (ROI) quantification was performed with ROVER (ABX GmbH). The ROI values were not corrected for recovery and partial volume effects. For each nanoPET/CT scan, 3D ROIs were drawn over the tumour, heart, muscle, liver, and kidneys in decay-corrected whole-body orthogonal images.
Statistical analyses were carried out with GraphPad Prism version 6 (GraphPad Software). The data expressed as mean ± SEM was submitted to a one-way analysis of variance (ANOVA) with post hoc Tukey's multiple comparisons test, with a single pooled variance. Values of P < 0.05 were considered statistically significant and indicated by an asterisk (*).
Human studies

A direct comparison between [
68 Ga]Ga-DATA-TOC and [ 68 Ga]Ga-DOTA-TOC was performed in a 46-year-old male patient with well-differentiated NET lesions in the body and tail of the pancreas as well as peritumoural lymph node metastases, first diagnosed in November 2012. The large primary tumour involving the stomach, the spleen, and the left adrenal gland was surgically resected (R2) by distal pancreatectomy, partial gastrectomy, splenectomy, left adrenalectomy, and omentectomy. Despite octreotide therapy, the disease was progressing, and in 2015, the patient was treated with peptide receptor radionuclide therapy (PRRT) 25 ]LTT-SS28 from hSST 2/3/5 -binding sites in HEK293-hSST 2/3/5 cell membranes using the pansomatostatin ligand LTT-SS28 as reference [28] [29] [30] . As shown in Fig. 2 nat Ga]Ga-DOTA-TOC were found to be hSST 2 preferring (Additional file 1: Table S1 ).
Small animal PET and biodistribution
Micro-PET imaging: specific tumour binding
In dynamic PET studies in NMRI-nude mice, the implanted allogenic subcutaneous MPC-mCherry tumour was clearly visible with both radiotracers. Figure 3 shows coronal sections of dynamic PET images summarised from 1 to 2 h p.i. (midframe time 90 min) for one animal each. In vivo data for [ 68 Ga]Ga-DATA-TOC and [ 68 Ga]Ga-DOTA-TOC are illustrated for one animal each under A and C, respectively. For both radiotracers, the micro-PET data show a high accumulation of the radiotracers in the tumours. On a quantitative scale, the SUV (given in Fig. 3 ) appears to be higher for [ 68 Ga]Ga-DOTA-TOC. However, the micro-PET data are affected by photon energies of 68 Ga, by partial volume and spill-over effects. Accordingly, for a quantitative and statistically relevant comparison, we performed ex vivo organ distributions with n = 9 animals, see below.
In addition to the absolute tumour uptake of the two tracers it is important to address the specificity of the binding. Figure 3 shows the in vivo data for [ 68 Concerning the kidneys visualised in Fig. 3 , kidney uptake is dependent in part on the individual hydration, urine flow of the mouse, and level of the anaesthesia. The figure shows individual mice at a specific time point during the PET study. The accumulation of the radiotracers in the kidney may differ across mice and from timepoint to timepoint. Consequently, kidney uptake is also addressed in the ex vivo biodistribution studies.
Micro-PET imaging: kinetics of tumour binding
The in vivo PET studies allow kinetic data for the SUV in several organs at different timepoints p.i. to be collected. Figure 4 shows the ratios between tumour and blood as SUV mean (tumour)/SUV mean (blood). The kinetic tumour-to-blood ratios of [ Tables S2  and S3 ) for quantitative comparison of tumour accumulation, distribution, and elimination in control and blocked state. Figure 5a shows values of uptake in terms of %ID, whilst Fig. 5b shows values in terms of SUV. Both graphs also show ratios derived from the results of the blocking studies.
The tumour uptake of [ 68 Ga]Ga-DATA-TOC and [ 68 Ga]Ga-DOTA-TOC at 1 h after injection was in the same range with SUVs of 3.41 ± 1.43 and 4.52 ± 1.96 (P = 0.2838), respectively. These quantitative and statistically relevant ex vivo data are consistent with the in vivo PET data shown in Fig. 3 .
Ex vivo biodistribution: specific tumour binding
The simultaneous injection of excess [Nal 3 ]octreotide clearly blocked the tumour accumulation for both radiotracers. The resulting activity concentrations were not statistically significantly different with 0.36 ± 0.17 SUV [ 68 Ga]Ga-DATA-TOC and 0.26 ± 0.09 SUV [
68 Ga]Ga--DOTA-TOC, P = 0.2145.
Ex vivo biodistribution: binding to other tissues
Blood and muscle: The blood concentration of [ 68 Ga]Ga-DATA-TOC (0.19 ± 0.08 SUV) was higher in comparison to [ 68 Ga]Ga-DOTA-TOC (0.06 ± 0.01 SUV; P < 0.01). This resulted in a lower tumour-to-blood ratio of 20.2 ± 11.9 vs. 70.5 ± 34.3; P < 0.01. However, the tumour-to-muscle ratios for both radiotracers were not statistically different with 103.0 ± 57.2 for [ 68 Ga]Ga-DATA-TOC and 157.0 ± 34.6 for [ 68 Ga]Ga-DOTA-TOC (P = ]octreotide acetate together with the radiotracer Fig. 6 post-tracer injection, demonstrated a similar, very intense hSST 2 -uptake in the primary pancreatic tumour (Fig. 6 ). There was a notable lower uptake of 68 Ga]Ga-DATA-TOC in normal liver (Table 1) 
Discussion
The novel TOC-conjugate, DATA-TOC, showed the potential to establish an instant kit-type labelling routine of clinically relevant vectors with 68 Ga [23, 33] . Radiolabelling with 68 Ga for animal studies was completed quantitatively at 20°C for DATA-TOC, whereas for DOTA-TOC a higher temperature was required to achieve comparable labelling efficiency. This finding corroborates previously reported radiochemical data for convenient and simple kit-type labelling of DATA-TOC with 68 Ga [23] . (Fig. 3) . Based on previous studies, such differences can be considered minimal for clinical translation given that many other critical factors (such as agonism or antagonism, stability, pharmacokinetics, or tumour residence times) greatly affect final clinical outcomes [28, 30, 34, 35] . Therefore, it is reasonable to conclude that the exchange of DOTA for the DATA chelator was well tolerated by the hSST 2 68 Ga]Ga-DATA-TOC resulted in a lower overall tumour uptake (SUV 46.9), a significantly better tumour-to-liver ratio of 5.2 (compared to 3.1 for [ 68 Ga]Ga-DOTA-TOC) could be achieved, which might enable better visualisation of liver metastases [37] .
The present study aimed to identify whether the new chelator DATA influences the affinity and pharmacology of the DATA-conjugated radiopharmaceutical [ 68 Ga]Ga-DATA-TOC relative to the industry standard [ 68 Ga]Ga-DOTA-TOC. The radiotracers displayed similar characteristics in terms of in vitro affinity and in vitro internalisation to SST-positive cell lines, as well in terms of organ distribution and uptake kinetics. [ 68 Ga]Ga-DATA-TOC displays high potential as a diagnostic agent in PET/CT, whilst its ease of preparation adds an important aspect to 
